NeoPharm CO. LTD Total Liabilities

Latest as of September 2025: ₩18.97 Billion KRW ≈ $12.86 Million USD

NeoPharm CO. LTD total liabilities. Based on the latest financial reports, NeoPharm CO. LTD (092730) has total liabilities worth ₩18.97 Billion KRW (≈ $12.86 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 092730 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of NeoPharm CO. LTD (2012–2024)

Total liabilities of NeoPharm CO. LTD from 2012 to 2024. This chart illustrates how NeoPharm CO. LTD's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of NeoPharm CO. LTD to see how much of total assets are deployed in long-term investments.

NeoPharm CO. LTD Competitors by Total Liabilities

The table below lists competitors of NeoPharm CO. LTD ranked by their total liabilities.

Company	Country	Total Liabilities
Grupo Clarin S.A. BA:GCLA	Argentina	AR$235.45 Billion
Neo Technical System Co. Ltd KQ:085910	Korea	₩49.58 Billion
KANGWON Co. Ltd KQ:114190	Korea	₩86.27 Billion
Innate Pharma NASDAQ:IPHA	USA	$84.39 Million
Ally Leasehold Real Estate Investment Trust BK:ALLY	Thailand	฿5.02 Billion
MC Mining Ltd AU:MCM	Australia	AU$30.20 Million
Aurskog Sparebank OL:AURG	Norway	Nkr19.65 Billion
E KOCREF CR REIT KO:088260	Korea	₩453.23 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down NeoPharm CO. LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of NeoPharm CO. LTD.

Liquidity & Leverage Metrics

NeoPharm CO. LTD Total Liabilities Ratios Explained

NeoPharm CO. LTD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	9.36	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.10	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.09	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NeoPharm CO. LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NeoPharm CO. LTD (2012–2024)

The table below shows the annual total liabilities of NeoPharm CO. LTD from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩15.56 Billion ≈ $10.54 Million	-10.77%
2023-12-31	₩17.43 Billion ≈ $11.81 Million	+32.70%
2022-12-31	₩13.14 Billion ≈ $8.90 Million	+0.26%
2021-12-31	₩13.10 Billion ≈ $8.88 Million	-14.14%
2020-12-31	₩15.26 Billion ≈ $10.34 Million	-10.49%
2019-12-31	₩17.05 Billion ≈ $11.55 Million	+24.98%
2018-12-31	₩13.64 Billion ≈ $9.24 Million	+49.69%
2017-12-31	₩9.11 Billion ≈ $6.18 Million	+14.80%
2016-12-31	₩7.94 Billion ≈ $5.38 Million	+1.96%
2015-12-31	₩7.79 Billion ≈ $5.28 Million	+84.58%
2012-12-31	₩4.22 Billion ≈ $2.86 Million	--

About NeoPharm CO. LTD

KQ:092730 Korea Personal & Household Products & Services

Market Cap

$124.79 Million

₩184.14 Billion KRW

Market Cap Rank

#18160 Global

#791 in Korea

Share Price

₩23050.00

Change (1 day)

+2.90%

52-Week Range

₩15760.00 - ₩25450.00

All Time High

₩27383.15